ISMP Recommended*1
A SOLUTION Is a
Valuable CHOICE
The rst and only FDA-approved
nimodipine oral solution, available in:
• 30 mg (10 mL) Unit Dose Cups
• 60 mg (20 mL) Unit Dose Cups
• 16 oz (473 mL) Bottle
*ISMP recommended for institutions that do not extract and dispense in an oral syringe from the pharmacy
Indication and Use
NYMALIZE is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with
subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I–V).
Important Safety Information
Blood pressure should be carefully monitored during treatment with Nymalize. Nimodipine may increase the blood pressure-lowering–effect of concomitantly
administered anti-hypertensives. Patients with cirrhosis are at a higher risk of adverse reactions and should be monitored closely and administered a lower dose.
Concomitant use of strong CYP3A4 inhibitors or inducers and nimodipine should generally be avoided. Nimodipine plasma concentration can also be increased
in the presence of moderate and weak inhibitors of CYP3A4. Ingestion of grapefruit/grapefruit juice is not recommended while taking nimodipine. Moderate and
weak inducers of CYP3A4 may also reduce the efficacy of nimodipine. The most common adverse reactions observed in registration trials were hypotension,
headache, nausea, and bradycardia.
For Full Prescribing Information please visit www.nymalize.com
ISMP=Institute for Safe Medication Practices.
1. Institute for Safe Medication Practices. ISMP quarterly action agenda April-June 2013: IV administration of oral liquid nimodipine. ISMP Medication Safety Alert.
July 11, 2013:QAA3-QAA4. https://www.ismp.org/newsletters/acutecare/ActionAgendas_PDF/ActionAgenda1303.pdf. Accessed August 9, 2016.
© 2017 Arbor Pharmaceuticals, LLC. All rights reserved. Nymalize® is a registered trademark of Arbor Pharmaceuticals, LLC PP-NYM-US-0293
